KR100770194B1 - 세로토닌 재흡수 억제제로서 페닐-피페라진 유도체 - Google Patents

세로토닌 재흡수 억제제로서 페닐-피페라진 유도체 Download PDF

Info

Publication number
KR100770194B1
KR100770194B1 KR1020047004897A KR20047004897A KR100770194B1 KR 100770194 B1 KR100770194 B1 KR 100770194B1 KR 1020047004897 A KR1020047004897 A KR 1020047004897A KR 20047004897 A KR20047004897 A KR 20047004897A KR 100770194 B1 KR100770194 B1 KR 100770194B1
Authority
KR
South Korea
Prior art keywords
compound
phenyl
piperazine
pharmaceutically acceptable
acid addition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020047004897A
Other languages
English (en)
Korean (ko)
Other versions
KR20040047886A (ko
Inventor
룰란트토마스
스미스개릭폴
방-안데르센베뉘
퓌슐아스크
몰트센아이네르크누드
안데르센킴
Original Assignee
하. 룬트벡 아크티에 셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100770194(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 하. 룬트벡 아크티에 셀스카브 filed Critical 하. 룬트벡 아크티에 셀스카브
Publication of KR20040047886A publication Critical patent/KR20040047886A/ko
Application granted granted Critical
Publication of KR100770194B1 publication Critical patent/KR100770194B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020047004897A 2001-10-04 2002-10-02 세로토닌 재흡수 억제제로서 페닐-피페라진 유도체 Expired - Lifetime KR100770194B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101466 2001-10-04
DKPA200101466 2001-10-04
PCT/DK2002/000659 WO2003029232A1 (en) 2001-10-04 2002-10-02 Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020067022562A Division KR100783346B1 (ko) 2001-10-04 2002-10-02 세로토닌 재흡수 억제제로서 페닐-피페라진 유도체

Publications (2)

Publication Number Publication Date
KR20040047886A KR20040047886A (ko) 2004-06-05
KR100770194B1 true KR100770194B1 (ko) 2007-10-25

Family

ID=8160750

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020047004897A Expired - Lifetime KR100770194B1 (ko) 2001-10-04 2002-10-02 세로토닌 재흡수 억제제로서 페닐-피페라진 유도체
KR1020067022562A Expired - Lifetime KR100783346B1 (ko) 2001-10-04 2002-10-02 세로토닌 재흡수 억제제로서 페닐-피페라진 유도체
KR1020077022025A Expired - Lifetime KR100842702B1 (ko) 2001-10-04 2002-10-02 세로토닌 재흡수 억제제로서 페닐-피페라진 유도체

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020067022562A Expired - Lifetime KR100783346B1 (ko) 2001-10-04 2002-10-02 세로토닌 재흡수 억제제로서 페닐-피페라진 유도체
KR1020077022025A Expired - Lifetime KR100842702B1 (ko) 2001-10-04 2002-10-02 세로토닌 재흡수 억제제로서 페닐-피페라진 유도체

Country Status (38)

Country Link
US (10) US7144884B2 (enExample)
EP (2) EP1436271B3 (enExample)
JP (3) JP3896116B2 (enExample)
KR (3) KR100770194B1 (enExample)
CN (1) CN1319958C (enExample)
AR (2) AR036659A1 (enExample)
AT (2) ATE386730T1 (enExample)
AU (2) AU2002333220C1 (enExample)
BE (1) BE2014C036I2 (enExample)
BR (3) BR122012023120B8 (enExample)
CA (1) CA2462110C (enExample)
CO (1) CO5580746A2 (enExample)
CY (3) CY1107924T1 (enExample)
DE (2) DE60233608D1 (enExample)
DK (2) DK1436271T6 (enExample)
EA (2) EA011096B1 (enExample)
EG (1) EG25095A (enExample)
ES (2) ES2298425T7 (enExample)
FR (1) FR14C0033I2 (enExample)
HR (1) HRP20040220A2 (enExample)
HU (3) HU228956B1 (enExample)
IL (1) IL160655A0 (enExample)
IS (2) IS2578B (enExample)
LT (1) LTC1436271I2 (enExample)
LU (1) LU92397I2 (enExample)
ME (1) ME00039B (enExample)
MX (1) MXPA04002959A (enExample)
MY (1) MY140950A (enExample)
NL (1) NL300652I1 (enExample)
NO (3) NO326443B1 (enExample)
NZ (1) NZ531556A (enExample)
PL (2) PL209253B1 (enExample)
PT (2) PT1436271E (enExample)
RS (2) RS52326B (enExample)
SI (1) SI1436271T1 (enExample)
UA (2) UA81749C2 (enExample)
WO (1) WO2003029232A1 (enExample)
ZA (1) ZA200401583B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190005679A (ko) 2017-07-07 2019-01-16 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
UA81300C2 (en) * 2003-04-04 2007-12-25 Lundbeck & Co As H Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
SI1626720T1 (sl) * 2003-04-04 2008-12-31 Lundbeck & Co As H Derivati 4-(2-fenilsulfanil-fenil)-piperidina kotzaviralci ponovnega vnosa serotonina
AR043966A1 (es) * 2003-04-04 2005-08-17 Lundbeck & Co As H Derivados de 4- ( 2-feniloxifenil) - piperidina o 1,2,3,6 -tetrahidropiridina como inhibidores de la recaptacion de la serotonina
BRPI0408647A (pt) * 2003-04-04 2006-03-07 Lundbeck & Co As H composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo
EP1635828B1 (en) * 2003-04-04 2008-04-23 H. Lundbeck A/S 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
DK1701940T3 (da) 2003-12-23 2008-09-08 Lundbeck & Co As H 2-(1H-indolylsulfanyl)-bensylaminderivater som SSRI
AR052308A1 (es) 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
DE602006007550D1 (de) * 2005-02-10 2009-08-13 Neurosearch As Alkylsubstituierte homopiperazinderivate und deren verwendung als monoamin neurotransmitter wiederaufnahmeinhibitoren
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
JP7179035B2 (ja) * 2006-06-16 2022-11-28 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
DK2044020T3 (da) * 2006-06-16 2011-08-15 Lundbeck & Co As H Krystallinske former af 4-[2-(4-methylphenylsulfanyl)-phenyl]-piperidin med kombineret serotonin- og norepinephrin-genoptagelsesinhibering til behandling af neuropatisk smerte
EP2439201B1 (en) * 2006-06-16 2013-08-07 H. Lundbeck A/S Compounds with combined sert, 5-ht3 and 5-ht1a activity
HRP20110412T1 (hr) * 2006-06-16 2011-06-30 H. Lundbeck A/S Kristalni oblici 4-[2-4-(4-metilfenilsulfanil)fenil]piperidina sa kombiniranom inhibicijom reapsorpcije serotonina i norepinefrina za liječenje neuropatskih bolova
CN101472891B (zh) * 2006-06-16 2013-08-21 H.隆德贝克有限公司 有神经病痛治疗用血清素和去甲肾上腺素再摄取综合抑制作用的4-[2-(4-甲基苯硫基)苯基]哌啶的结晶形式
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TWI405588B (zh) 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
JP5764327B2 (ja) * 2007-06-15 2015-08-19 ハー・ルンドベック・アクチエゼルスカベット 過敏性腸症候群（ｉｂｓ）を処置するための４−［２−（４−メチルフェニルスルファニル）フェニル］ピペリジン
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
WO2009081259A1 (en) * 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
UA98698C2 (en) 2008-03-03 2012-06-11 Х. Луннбек А/С Phenylsulfanylphenyl-piperidines and process for the preparation thereof
MX2011005089A (es) 2008-11-14 2011-07-29 Theravance Inc Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina.
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
HRP20140880T1 (hr) * 2009-04-24 2014-11-07 H. Lundbeck A/S Tekuä†a formulacija soli 1-/2-(2,4 dimetilfenilsulfanil)fenil/piperazina
ME01602B (me) * 2009-08-24 2014-09-20 H Lundbeck As Nove kompozicije 1-[2 -(2,4-dimetil-fenilsulfanil)-fenil]piperazina
WO2011053706A1 (en) * 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators
WO2011085291A1 (en) * 2010-01-11 2011-07-14 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
ES2543064T3 (es) * 2010-03-22 2015-08-14 Theravance Biopharma R&D Ip, Llc Compuestos de 1-(2-fenoximetilheteroaril)piperidina y piperazina
US8920840B2 (en) * 2010-04-30 2014-12-30 Takeda Pharmaceutical Company Limited Enteric tablet
EP2564838A4 (en) * 2010-04-30 2014-06-04 Takeda Pharmaceutical ENTERICIAN TABLET
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
TW201212918A (en) * 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
ES2719145T3 (es) 2011-06-20 2019-07-08 H Lundbeck As 1-Piperazino-3-fenil-indanos deuterados para el tratamiento de la esquizofrenia
AU2012340015B2 (en) 2011-11-14 2017-09-21 Alfasigma S.P.A. Assays for selecting a treatment regimen for a subject with depression and methods for treatment
SG11201403835UA (en) * 2012-01-03 2014-10-30 Lundbeck & Co As H Process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine
CN104797566B (zh) 2012-09-19 2017-07-07 桑多斯股份公司 沃替西汀氢溴酸盐的新结晶形式
KR102171152B1 (ko) 2012-12-13 2020-10-29 하. 룬드벡 아크티에셀스카브 보르티옥세틴 및 도네페질을 포함하는 조성물
RS55932B1 (sr) * 2013-02-22 2017-09-29 H Lundbeck As Postupak za proizvodnju vortioksetina
SI2981520T1 (sl) * 2013-04-04 2019-07-31 Lek Pharmaceuticals D.D. Novi proces za sintezo 1-(2-((2,4-dimetilfenil)tio)fenil)piperazina
CN104109135B (zh) * 2013-04-22 2018-10-26 江苏豪森药业集团有限公司 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法
US10414741B2 (en) 2013-09-30 2019-09-17 Cadila Healthcare Limited Amorphous vortioxetine and salts thereof
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN104710345B (zh) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
AU2014368548B2 (en) 2013-12-20 2019-09-19 H. Lundbeck A/S Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
EP2894154A1 (en) 2014-01-14 2015-07-15 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
EP3099669A1 (en) 2014-01-31 2016-12-07 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
EP2930171A1 (en) 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104059030B (zh) 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
FR3023320B1 (fr) * 2014-07-03 2017-03-10 Ifp Energies Now Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial
CZ2014471A3 (cs) 2014-07-08 2016-01-20 Zentiva, K.S. Způsob přípravy vortioxetinu
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104292183B (zh) * 2014-09-29 2016-01-06 杨献美 一种抗抑郁药物沃替西汀的制备方法
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
ES2634496T3 (es) 2014-11-21 2017-09-28 Dipharma Francis S.R.L. Proceso para la preparación de un antidepresivo y los intermedios del mismo
CN104447622B (zh) * 2014-11-28 2017-01-04 郑州大明药物科技有限公司 氢溴酸沃替西汀β晶型的制备方法
CN104586756A (zh) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 一种含沃替西汀的口服溶液及其制备方法
CZ201531A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Polymerem stabilizované amorfní formy vortioxetinu
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
AU2016224930A1 (en) 2015-02-25 2017-09-07 Lupin Limited Process for the preparation of Vortioxetine
EP3274330A1 (en) 2015-03-26 2018-01-31 Cipla Limited Method for making serotonin reuptake inhibitors
CN104829557B (zh) * 2015-04-23 2017-06-27 山东百诺医药股份有限公司 一种新化合物1‑[2‑（2,4‑二甲基苯基硫基）苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
CA2992161A1 (en) * 2015-07-17 2017-01-26 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
WO2017029377A1 (en) * 2015-08-19 2017-02-23 Amneal Pharmaceuticals Company Gmbh Process for preparation of vortioxetine hydrobromide
US20180303772A1 (en) * 2015-10-14 2018-10-25 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
CN105461635B (zh) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
US11013830B2 (en) 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
BR112018003930A2 (pt) 2016-07-01 2018-09-25 H Lundbeck As regimes de dosagem de vortioxetina para início rápido de efeito antidepressivo
WO2018011382A1 (en) 2016-07-15 2018-01-18 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair
JP2019523256A (ja) * 2016-07-22 2019-08-22 ジアンス・エンファルオカン・ファーマスーティカル・リサーチ・アンド・デベロップメント・カンパニー・リミテッドＪｉａｎｇｓｕ Ｎｈｗａｌｕｏｋａｎｇ Ｐｈａｒｍｃｅｕｔｉｃａｌ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．，Ｌｔｄ． ボルチオキサチン類似化合物、その用途及びその製造
WO2018042168A1 (en) 2016-08-29 2018-03-08 King, Lawrence Stable pharmaceutical composition of vortioxetine hydrobromide
CN106349132B (zh) * 2016-08-30 2018-02-02 重庆植恩药业有限公司 沃替西汀中间体杂质及其制备方法和用途
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN108409728B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
CN108409729B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
US10428033B2 (en) 2017-02-15 2019-10-01 Piramal Enterprises Limited Process for the preparation of vortioxetine and salts thereof
EP3582759A4 (en) 2017-02-17 2021-01-06 Unichem Laboratories Ltd BIOEQUIVALENT PHARMACEUTICAL COMPOSITION OF VORTIOXETINE BROMHYDRATE
WO2018154451A1 (en) * 2017-02-23 2018-08-30 Unichem Laboratories Ltd An improved process for preparation and purification of vortioxetine hydrobromide
HUE057993T2 (hu) * 2017-04-25 2022-06-28 H Lundbeck As Eljárás vortioxetin-HBr alfa-forma elõállítására
EP3412661A1 (en) 2017-06-08 2018-12-12 Enantia, S.L. Cocrystals of vortioxetine hydrobromide and resorcinol
CN107915685A (zh) * 2017-12-11 2018-04-17 重庆植恩药业有限公司 一种氢溴酸沃替西汀中间体的制备方法
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
PL3810582T3 (pl) 2018-06-20 2024-05-13 Vio Ag Pharmaceuticals S.A. Jednonaczyniowy sposób organopseudokatalitycznej aktywacji c-h do wytwarzania wortioksetyny i związku pośredniego wortioksetyny
CN108863986B (zh) * 2018-08-06 2020-01-21 广东东阳光药业有限公司 二氟甲基取代的苯基哌嗪衍生物及其用途
CN108727393B (zh) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 苯基二氮杂双环衍生物及其用途
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2021198778A1 (en) 2020-04-03 2021-10-07 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting
WO2022052391A1 (zh) 2020-09-10 2022-03-17 苏州富德兆丰生化科技有限公司 伏硫西汀的合成方法
GB2622880A (en) 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine
WO2025132869A1 (en) 2023-12-21 2025-06-26 H. Lundbeck A/S Method for the preparation of vortioxetine pharmaceutical compositions with low amounts of nitrosamine impurities
CN120774863A (zh) * 2024-04-02 2025-10-14 王春刚 一种烷基二胺取代双芳杂环基硫醚类化合物及其制备和在制备治疗和/或预防肿瘤药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1489711A (en) 1975-07-21 1977-10-26 Science Union & Cie 1-phenoxyphenyl-piperazine derivatives process for their preparation and pharmaceutical compositions containing the
EP0755923A1 (en) 1995-01-23 1997-01-29 Suntory Limited Ameliorant or remedy for symptoms caused by ischemic diseases and compounds useful therefor
WO2001049678A1 (en) 1999-12-30 2001-07-12 H. Lundbeck A/S Substituted phenyl-piperazine derivatives, their preparation and use
WO2001049681A1 (en) * 1999-12-30 2001-07-12 H. Lundbeck A/S A method for the preparation of substituted benzene derivatives

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS151753B1 (enExample) 1971-04-13 1973-11-19
CS151752B1 (enExample) 1971-04-13 1973-11-19
CS151755B1 (enExample) 1971-04-13 1973-11-19
CS151751B1 (enExample) 1971-04-13 1973-11-19
US4241071A (en) * 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198419A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenylthiophenylpiperidines
US4198417A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
ES2004809A6 (es) 1987-07-29 1989-02-01 Ferrer Int Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DE69830045T2 (de) * 1997-10-31 2006-01-12 Daiichi Suntory Pharma Co., Ltd. Arylpiperidinopropanol und Arylpiperazinopropanol Derivate und dieselbe ent- haltende Pharmazeutika
CN1721401A (zh) 1999-04-02 2006-01-18 伊科斯公司 白细胞功能相关抗原与细胞间粘着分子结合的抑制剂及其用途
WO2001010842A2 (en) 1999-08-04 2001-02-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
AU766592B2 (en) * 1999-09-14 2003-10-16 Pharmacopeia, Inc. Article comprising a multi-channel dispensing head
US6813639B2 (en) 2000-01-26 2004-11-02 Viaclix, Inc. Method for establishing channel-based internet access network
DE10033548C2 (de) 2000-07-11 2002-05-16 Wolfgang Papenbrock Verfahren zur Vorschau von Internetseiten
JP2004523530A (ja) * 2001-01-23 2004-08-05 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニストとしてのピペラジンおよびピペリジン誘導体
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
CN100457738C (zh) * 2001-12-20 2009-02-04 H·隆德贝克有限公司 芳氧基苯基和芳硫基苯基衍生物
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
SI1626720T1 (sl) * 2003-04-04 2008-12-31 Lundbeck & Co As H Derivati 4-(2-fenilsulfanil-fenil)-piperidina kotzaviralci ponovnega vnosa serotonina
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP2439201B1 (en) * 2006-06-16 2013-08-07 H. Lundbeck A/S Compounds with combined sert, 5-ht3 and 5-ht1a activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1489711A (en) 1975-07-21 1977-10-26 Science Union & Cie 1-phenoxyphenyl-piperazine derivatives process for their preparation and pharmaceutical compositions containing the
EP0755923A1 (en) 1995-01-23 1997-01-29 Suntory Limited Ameliorant or remedy for symptoms caused by ischemic diseases and compounds useful therefor
WO2001049678A1 (en) 1999-12-30 2001-07-12 H. Lundbeck A/S Substituted phenyl-piperazine derivatives, their preparation and use
WO2001049681A1 (en) * 1999-12-30 2001-07-12 H. Lundbeck A/S A method for the preparation of substituted benzene derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190005679A (ko) 2017-07-07 2019-01-16 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법

Also Published As

Publication number Publication date
CA2462110A1 (en) 2003-04-10
AU2002333220B2 (en) 2008-02-07
US7144884B2 (en) 2006-12-05
HU230189B1 (hu) 2015-09-28
PT1749818E (pt) 2009-10-06
EA011096B1 (ru) 2008-12-30
US9708280B2 (en) 2017-07-18
LTPA2014013I1 (lt) 2014-04-25
JP3896116B2 (ja) 2007-03-22
AU2006215994A2 (en) 2006-10-05
AU2002333220A2 (en) 2003-04-14
HRP20040220A2 (en) 2005-02-28
CY2014022I2 (el) 2015-12-09
NL300652I2 (enExample) 2016-01-18
NO2014011I2 (no) 2015-08-31
DE60225162D1 (de) 2008-04-03
US20180127389A1 (en) 2018-05-10
SI1436271T1 (sl) 2008-06-30
DK1436271T6 (da) 2022-06-27
US20120302553A1 (en) 2012-11-29
ME00039B (me) 2010-06-10
US9090575B2 (en) 2015-07-28
US7138407B2 (en) 2006-11-21
US20060089368A1 (en) 2006-04-27
PL210551B1 (pl) 2012-02-29
BR0212733B1 (pt) 2014-05-13
HUS1400012I1 (hu) 2020-12-28
RS20120158A3 (en) 2013-10-31
ATE386730T1 (de) 2008-03-15
AR066460A2 (es) 2009-08-19
PL368442A1 (pl) 2005-03-21
BR0212733A (pt) 2004-11-16
KR20060118020A (ko) 2006-11-17
IS8806A (is) 2009-03-10
PT1436271E (pt) 2008-04-10
ES2298425T7 (es) 2022-06-27
HUP0402313A2 (hu) 2005-02-28
IS2732B (is) 2011-04-15
DE60225162T2 (de) 2009-02-12
US20050014740A1 (en) 2005-01-20
AU2006215994A1 (en) 2006-10-05
CA2462110C (en) 2010-05-11
EP1436271B3 (en) 2022-04-20
ATE441631T1 (de) 2009-09-15
IS7164A (is) 2004-02-26
JP3955613B2 (ja) 2007-08-08
US20140163043A1 (en) 2014-06-12
NL300652I1 (enExample) 2016-01-18
HK1072600A1 (zh) 2005-09-02
ES2328725T3 (es) 2009-11-17
HUP0402313A3 (en) 2010-03-29
ES2298425T3 (es) 2008-05-16
EP1749818A3 (en) 2008-04-02
EP1436271B1 (en) 2008-02-20
EA200601269A1 (ru) 2007-02-27
US20210276966A1 (en) 2021-09-09
BR122012023120B8 (pt) 2022-01-18
AU2002333220C1 (en) 2023-10-05
NO20041628L (no) 2004-04-21
JP2007051149A (ja) 2007-03-01
US20060084662A1 (en) 2006-04-20
UA93857C2 (uk) 2011-03-25
AR036659A1 (es) 2004-09-22
KR20070103515A (ko) 2007-10-23
MEP6508A (xx) 2010-02-10
DK1749818T3 (da) 2009-10-12
CY2014022I1 (el) 2015-12-09
JP2005505585A (ja) 2005-02-24
EA007537B1 (ru) 2006-10-27
US10844029B2 (en) 2020-11-24
EG25095A (en) 2011-08-17
NO332355B1 (no) 2012-09-03
NO20083446L (no) 2004-04-21
US20070060574A1 (en) 2007-03-15
BR122012023120B1 (pt) 2017-03-21
EA007537B3 (ru) 2015-02-27
KR100842702B1 (ko) 2008-07-01
AU2006215994A9 (en) 2006-10-05
LTC1436271I2 (lt) 2016-09-12
CN1319958C (zh) 2007-06-06
CO5580746A2 (es) 2005-11-30
JP3955614B2 (ja) 2007-08-08
BR122012009534C8 (pt) 2021-05-25
DE60225162T3 (de) 2022-08-11
RS20120158A2 (sr) 2012-10-31
UA81749C2 (uk) 2008-02-11
US8110567B2 (en) 2012-02-07
ZA200401583B (en) 2005-05-25
CY1107924T1 (el) 2013-09-04
US7683053B2 (en) 2010-03-23
IL160655A0 (en) 2004-07-25
BR122012009534B8 (pt) 2019-01-29
AU2006215994B2 (en) 2008-11-13
CN1561336A (zh) 2005-01-05
IS2578B (is) 2010-02-15
EP1749818A2 (en) 2007-02-07
EP1749818B1 (en) 2009-09-02
HU228956B1 (en) 2013-07-29
EP1436271A1 (en) 2004-07-14
BRPI0212733B8 (pt) 2021-05-25
NZ531556A (en) 2005-12-23
RS52326B (sr) 2012-12-31
US7148238B2 (en) 2006-12-12
DK1436271T3 (da) 2008-06-09
RS52865B (sr) 2013-12-31
BR122012009534B1 (pt) 2018-02-27
KR100783346B1 (ko) 2007-12-07
RS27704A (sr) 2006-10-27
PL209253B1 (pl) 2011-08-31
NO326443B1 (no) 2008-12-08
FR14C0033I2 (fr) 2014-11-14
US20110009423A1 (en) 2011-01-13
DE60233608D1 (de) 2009-10-15
CY1110064T1 (el) 2015-01-14
NO2014011I1 (no) 2014-05-13
US20160137620A1 (en) 2016-05-19
FR14C0033I1 (enExample) 2014-06-13
JP2007031447A (ja) 2007-02-08
WO2003029232A1 (en) 2003-04-10
US8476279B2 (en) 2013-07-02
EA200400498A1 (ru) 2004-08-26
KR20040047886A (ko) 2004-06-05
MXPA04002959A (es) 2004-07-05
BE2014C036I2 (enExample) 2021-11-22
MY140950A (en) 2010-02-12
LU92397I2 (fr) 2014-05-12
CA2462110E (en) 2003-04-10

Similar Documents

Publication Publication Date Title
KR100770194B1 (ko) 세로토닌 재흡수 억제제로서 페닐-피페라진 유도체
AU2002333220A1 (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040402

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20060602

Comment text: Request for Examination of Application

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20061027

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070508

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20070904

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20071019

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20071019

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20101012

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20110830

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20120924

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20120924

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20130926

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20130926

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20140923

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20140923

Start annual number: 8

End annual number: 8

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

Patent event date: 20141016

Patent event code: PA01011R01D

Comment text: Application to Register Extension of Term of Patent Right by Permit, etc.

FPAY Annual fee payment

Payment date: 20150918

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20150918

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20160921

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20160921

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20170919

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20170919

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20180918

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20180918

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20200928

Start annual number: 14

End annual number: 14

PR1001 Payment of annual fee

Payment date: 20210915

Start annual number: 15

End annual number: 15

PR1001 Payment of annual fee

Payment date: 20220915

Start annual number: 16

End annual number: 16

PR1001 Payment of annual fee

Payment date: 20230918

Start annual number: 17

End annual number: 17

PR1001 Payment of annual fee

Payment date: 20240919

Start annual number: 18

End annual number: 18